Comparing Metabolic and Immune Features in Primary Central Nervous System Lymphoma
Compares metabolic and immune features in adults with lymphoma starting in the central nervous system.
Plain-language title generated from the registry record
Registry title: Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Key facts
- Where
- Fuzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07188077, who can take part
Where in China
- The First Affiliated Hospital of Fujian Medical UniversityFuzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ting YANG
- Trial code
- NCT07188077
- Record updated
- 18 November 2025
- Original description
This study is a prospective cohort study. The case group will include patients with primary central nervous system lymphoma confirmed by imaging and pathology. The control group will include patients with pathologically confirmed diffuse large B-cell lymphoma who have been excluded from central nervous system involvement, as well as age- and gender-matched healthy volunteers (hematopoietic stem cell donors). Baseline data (as described below) will be collected. Patients with primary CNS lymphoma will undergo follow-up every 3 months, with immediate follow-up if clinical symptoms arise.Read full original descriptionShow less
Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma Based on Metabolomics and Immunomics
This study is a prospective cohort study. The case group will include patients with primary central nervous system lymphoma confirmed by imaging and pathology. The control group will include patients with pathologically confirmed diffuse large B-cell lymphoma who have been excluded from central nervous system involvement, as well as age- and gender-matched healthy volunteers (hematopoietic stem cell donors). Baseline data (as described below) will be collected. Patients with primary CNS lymphoma will undergo follow-up every 3 months, with immediate follow-up if clinical symptoms arise.
Inclusion: Aged between 18 and 75 years; The case group must have a confirmed diagnosis of primary central nervous system lymphoma (PCNSL) and must not have received any antitumor therapy prior to baseline sample collection; Must sign an informed consent form, agree to participate in this study, and provide samples and clinical information as required; Case group patients must have complete supporting imaging and pathology data.
Exclusion: Use of antimetabolites or chemotherapy drugs within one week prior to sample collection; Concurrent severe internal medical conditions (e.g., end-stage renal disease, heart failure, liver failure); Presence of other systemic malignancies; Presence of severe infections or metabolic disorders; Patients unable to complete study requirements due to psychiatric disorders or cognitive impairment; Pregnant or lactating women.